Last reviewed · How we verify
NCT04221282: ZEBRE
ZEBinix® Retention Rate in Epilepsy in Elderly Patients
trial testing Zebinix in Epilepsy in 50 participants. Status unknown.
30 September 2020
Quick facts
| Lead sponsor | Centre Hospitalier Saint Joseph Saint Luc de Lyon |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 1 April 2019 |
| Primary completion | 30 September 2020 |
| Estimated completion | 30 September 2020 |
| Sites | 1 location across France |
Drugs / interventions tested
- Zebinix — full drug profile →
Conditions studied
- Epilepsy — all drugs for Epilepsy →
- Aging Disorder — all drugs for Aging Disorder →
- Aging — all drugs for Aging →
- Epilepsy; Seizure — all drugs for Epilepsy; Seizure →
Sponsor
Centre Hospitalier Saint Joseph Saint Luc de Lyon
Who can join
65 and older, any sex, with Epilepsy or Aging Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The incidence of provoked and unprovoked seizures is known to increase with advancing age. Eslicarbazepine acetate (ESL) is one of the third generation of antiepileptic drugs (AEDs) that have been developed in the last ten years with a favorable safety profile. ESL is approved in Europe and the USA as adjunctive or monotherapy in adults with partial-onset seizures. Nevertheless, retrospective data in monotherapy condition in the elderly epileptic population are sparse. The aim of the ZEBRE study is to evaluate the efficacy and the safety of ESL in elderly epileptic patients (\> 65 years). The completion of this study will provide crucial information on the most appropriate ESL treatment for elderly patients suffering from partial seizures.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04221282
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Epilepsy
Currently open trials in the same condition.
- NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
- NCT07224191 — Hippocampal Oscillations During Exploration · NA · recruiting
- NCT07219407 — A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures · Phase 2 · recruiting
- NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
- NCT07490769 — Levetiracetam Three Times Daily in Epilepsy · Phase 3 · recruiting
Other Centre Hospitalier Saint Joseph Saint Luc de Lyon trials
Trials by the same sponsor.
- NCT07312890 — Bedside Observation by Clinical Ultrasound for Stomach Expansion · NA · recruiting
- NCT07355777 — Video Tutorial and Oral Explanation Vs Oral Explanation Alone in Colonoscopy Preparation · NA · recruiting
- NCT04827290 — Assessment of the Effect of Restriction on Alimentary AGE in Progression of Chronic Kidney Disease · NA · not yet recruiting
- NCT04641650 — Pilot Study : FreeStyle Libre Pro Flash Continuous Glucose Monitoring System in Subjects With Diabetes on HemoDIALsis · completed
- NCT04422977 — Serological Study of the Exposure of Personnel to COVID-19 · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04221282 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Saint Joseph Saint Luc de Lyon
- Last refreshed: 9 January 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04221282.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing